Nonalcoholic fatty liver disease (NAFLD) has reached epidemic proportions worldwide.
NAFLD and type 2 diabetes mellitus (T2DM) are known to frequently coexist and act …

The 1921 discovery of insulin was a Big Bang from which a vast and expanding universe of
research into insulin action and resistance has issued. In the intervening century, some …

The centenary of insulin discovery represents an important opportunity to transform diabetes
from a fatal diagnosis into a medically manageable chronic condition. Insulin is a key …

Insulin resistance, defined as a defect in insulin-mediated control of glucose metabolism in
tissues—prominently in muscle, fat and liver—is one of the earliest manifestations of a …

Non-alcoholic fatty liver disease (NAFLD) has emerged pandemically across the globe and
particularly affects patients with obesity and type 2 diabetes. NAFLD is a complex systemic …

Insulin resistance is a forerunner state of ischaemic cardiovascular disease and type 2
diabetes. Here we show how the human gut microbiome impacts the serum metabolome …

Sphingolipids, including the two central bioactive lipids ceramide and sphingosine-1-
phosphate (S1P), have opposing roles in regulating cancer cell death and survival …

The pathogenesis of non-alcoholic fatty liver disease, particularly the mechanisms whereby
a minority of patients develop a more severe phenotype characterised by hepatocellular …

Background and Aims NAFLD is characterized by insulin resistance and dysregulated lipid
and glucose metabolism. Saroglitazar, a dual peroxisome proliferator activated receptor‐α/γ …

Increases in calorie consumption and sedentary lifestyles are fuelling a global pandemic of
cardiometabolic diseases, including coronary artery disease, diabetes mellitus …